Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
Status:
RECRUITING
Trial end date:
2029-03-31
Target enrollment:
Participant gender:
Summary
This study is conducted to evaluate the efficacy and safety of lenvatinib plus SIRT (LEN+SIRT) compared with lenvatinib (LEN) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).
Phase:
PHASE2
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University